FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene (DOI:10.1016/j.cell.2007.04.034);FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important Repressor of the HER-2/ErbB2 Oncogene

Cell

Volumn 129, Issue 7, 2007, Pages 1275-1286

  Zuo, Tao ^b   Wang, Lizhong ^a   Morrison, Carl ^c   Chang, Xing ^a   Zhang, Huiming ^a   Li, Weiquan ^a   Liu, Yan ^a   Wang, Yin ^a   Liu, Xingluo ^c   Chan, Michael W Y ^b   Liu, Jin Qing ^c   Love, Richard ^c   Liu, Chang gong ^b   Godfrey, Virginia ^d   Shen, Rulong ^c   Huang, Tim H M ^b   Yang, Tianyu ^c   Park, Bae Keun ^e   Wang, Cun Yu ^e   Zheng, Pan ^a   Liu, Yang ^a   more..

^a Section of General Surgery   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

HUMDISEASE

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSCRIPTION FACTOR FOXP3;

ALLELE; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; GENE AMPLIFICATION; GENE CONTROL; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE NEU; PRIORITY JOURNAL; SOMATIC MUTATION; X CHROMOSOME LINKED DISORDER;

MUS;

EID: 34250863911     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2008.07.036     Document Type: Erratum

References (35)

1. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., Kelly T.E., Saulsbury F.T., Chance P.F., and Ochs H.D. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27 (2001) 20-21
2. Bofin A.M., Ytterhus B., Martin C., O'Leary J.J., and Hagmar B.M. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am. J. Clin. Pathol. 122 (2004) 110-119
3. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., Wilkinson J.E., Galas D., Ziegler S.F., and Ramsdell F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27 (2001) 68-73
4. Chang X., Gao J.X., Jiang Q., Wen J., Seifers N., Su L., Godfrey V.L., Zuo T., Zheng P., and Liu Y. The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. J. Exp. Med. 202 (2005) 1141-1151
5. Chatila T.A., Blaeser F., Ho N., Lederman H.M., Voulgaropoulos C., Helms C., and Bowcock A.M. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. 106 (2000) R75-R81
6. Dai M., Wang P., Boyd A.D., Kostov G., Athey B., Jones E.G., Bunney W.E., Myers R.M., Speed T.P., Akil H., et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33 (2005) e175
7. Fontenot J.D., Gavin M.A., and Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4 (2003) 330-336
8. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., and Rudensky A.Y. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22 (2005) 329-341
9. Garcia de Palazzo I., Klein-Szanto A., and Weiner L.M. Immunohistochemical detection of c-erbB-2 expression by neoplastic human tissue using monospecific and bispecific monoclonal antibodies. Int. J. Biol. Markers 8 (1993) 233-239
10. Godfrey V.L., Wilkinson J.E., Rinchik E.M., and Russell L.B. Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: potential model for thymic education. Proc. Natl. Acad. Sci. USA 88 (1991) 5528-5532
11. Godfrey V.L., Rouse B.T., and Wilkinson J.E. Transplantation of T cell-mediated, lymphoreticular disease from the scurfy (sf) mouse. Am. J. Pathol. 145 (1994) 281-286
12. Im H., Grass J.A., Johnson K.D., Boyer M.E., Wu J., and Bresnick E.H. Measurement of protein-DNA interactions in vivo by chromatin immunoprecipitation. Methods Mol. Biol. 284 (2004) 129-146
13. Jimenez R.E., Wallis T., Tabasczka P., and Visscher D.W. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol. 13 (2000) 37-45
14. Kallioniemi O.P., Kallioniemi A., Kurisu W., Thor A., Chen L.C., Smith H.S., Waldman F.M., Pinkel D., and Gray J.W. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc. Natl. Acad. Sci. USA 89 (1992) 5321-5325
15. Knudson Jr. A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68 (1971) 820-823
16. Kristiansen M., Knudsen G.P., Maguire P., Margolin S., Pedersen J., Lindblom A., and Orstavik K.H. High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer. J. Med. Genet. 42 (2005) 877-880
17. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L.M., Ding W., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 (1994) 66-71
18. Piao Z., and Malkhosyan S.R. Frequent loss Xq25 on the inactive X chromosome in primary breast carcinomas is associated with tumor grade and axillary lymph node metastasis. Genes Chromosomes Cancer 33 (2002) 262-269
19. Richardson A.L., Wang Z.C., De Nicolo A., Lu X., Brown M., Miron A., Liao X., Iglehart J.D., Livingston D.M., and Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9 (2006) 121-132
20. Romanov S.R., Kozakiewicz B.K., Holst C.R., Stampfer M.R., Haupt L.M., and Tlsty T.D. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409 (2001) 633-637
21. Roncuzzi L., Brognara I., Cocchi S., Zoli W., and Gasperi-Campani A. Loss of heterozygosity at pseudoautosomal regions in human breast cancer and association with negative hormonal phenotype. Cancer Genet. Cytogenet. 135 (2002) 173-176
22. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
23. Schechter A.L., Stern D.F., Vaidyanathan L., Decker S.J., Drebin J.A., Greene M.I., and Weinberg R.A. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312 (1984) 513-516
24. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
25. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001) 783-792
26. Spatz A., Borg C., and Feunteun J. X-Chromosome genetics and human cancer. Nat. Rev. Cancer 4 (2004) 617-629
27. Todorovic-Rakovic N., Jovanovic D., Neskovic-Konstantinovic Z., and Nikolic-Vukosavljevic D. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer. Pathol. Int. 55 (2005) 318-323
28. Wang C.Y., Cusack Jr. J.C., Liu R., and Baldwin Jr. A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med. 5 (1999) 412-417
29. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297 (2002) 63-64
30. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., Levy-Lahad E., Mazzella M., Goulet O., Perroni L., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27 (2001) 18-20
31. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., and Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 378 (1995) 789-792
32. Wooster R., and Weber B.L. Breast and ovarian cancer. N. Engl. J. Med. 348 (2003) 2339-2347
33. Xing X., Wang S.C., Xia W., Zou Y., Shao R., Kwong K.Y., Yu Z., Zhang S., Miller S., Huang L., and Hung M.C. The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat. Med. 6 (2000) 189-195
34. Yaziji H., Goldstein L.C., Barry T.S., Werling R., Hwang H., Ellis G.K., Gralow J.R., Livingston R.B., and Gown A.M. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291 (2004) 1972-1977
35. Ziegler S.F. FOXP3: Of mice and men. Annu. Rev. Immunol. 24 (2006) 209-226